Echosens and Boehringer Ingelheim have expanded their collaboration aimed at expediting progress in metabolic ...

As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of liver failure—affecting more than 250 million people worldwide—Echosens, ...

This expansion will change the trajectory of MASH by focusing on early detection, diagnosis, and access to care.

By combining their diagnostic and therapeutic expertise, Echosens and Boehringer Ingelheim aim to help close persistent gaps ...

WALTHAM, Mass. & FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Echosens North America, a high-technology company offering the FibroScan ® portfolio of solutions, and ChronWell, a digital health and ...

PARIS, Aug. 26, 2024 /PRNewswire/ -- Echosens is thrilled to unveil the inaugural Liver Health Super Shaper Award, a heartfelt initiative designed to celebrate the extraordinary medical ...

To address this global health crisis, Echosens has launched its Liver Health Management (LHM) platform—a cloud-based solution designed to streamline liver disease care for healthcare providers ...

WESTBOROUGH, Mass., Dec. 9, 2024 /PRNewswire/ -- Echosens, the leader in liver health, is proud to be recognized as one of the 2024 Top Places to Work in Massachusetts, earning a spot among the ...

Echosens SA obtained clearance from the U.S. FDA to expand the indications for screening with its Fibroscan system. The approval removes contraindications for pregnancy and active implant and includes ...

By combining their diagnostic and therapeutic expertise, Echosens and Boehringer Ingelheim aim to help close persistent gaps in awareness, real-world evidence, and clinical adoption. This next ...